American Association for Cancer Research
Browse
00085472can093788-sup-methods_figleg.pdf (46.87 kB)

Supplementary Methods, Figure Legend from Molecular Target Class Is Predictive of In vitro Response Profile

Download (46.87 kB)
journal contribution
posted on 2023-03-30, 20:07 authored by Joel Greshock, Kurtis E. Bachman, Yan Y. Degenhardt, Junping Jing, Yuan H. Wen, Stephen Eastman, Elizabeth McNeil, Christopher Moy, Ronald Wegrzyn, Kurt Auger, Mary Ann Hardwicke, Richard Wooster
Supplementary Methods, Figure Legend from Molecular Target Class Is Predictive of In vitro Response Profile

History

ARTICLE ABSTRACT

Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficacy using cohorts of in vitro tumor models have been successful, expansive panels of tumor-derived cell lines can recapitulate an “all comers” efficacy trial, thereby identifying which tumors are most likely to benefit from treatment. The response profile of a therapy is most often studied in isolation; however, drug treatment effect patterns in tumor models across a diverse panel of compounds can help determine the value of unique molecular target classes in specific tumor cohorts. To this end, a panel of 19 compounds was evaluated against a diverse group of cancer cell lines (n = 311). The primary oncogenic targets were a key determinant of concentration-dependent proliferation response, as a total of five of six, four of four, and five of five phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, insulin-like growth factor-I receptor (IGF-IR), and mitotic inhibitors, respectively, clustered with others of that common target class. In addition, molecular target class was correlated with increased responsiveness in certain histologies. A cohort of PI3K/AKT/mTOR inhibitors was more efficacious in breast cancers compared with other tumor types, whereas IGF-IR inhibitors more selectively inhibited growth in colon cancer lines. Finally, specific phenotypes play an important role in cellular response profiles. For example, luminal breast cancer cells (nine of nine; 100%) segregated from basal cells (six of seven; 86%). The convergence of a common cellular response profile for different molecules targeting the same oncogenic pathway substantiates a rational clinical path for patient populations most likely to benefit from treatment. Cancer Res; 70(9); 3677–86. ©2010 AACR.